Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.44 |
| ▸ | NPY1R | P25929 | 7/20 | 0.44 |
| ▸ | NPY2R | P49146 | 5/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8507718 | 1.00 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL3042600 | 0.88 | NPY4R (0.42) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL4099155 | 0.87 | NPY4R (0.39) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL27824286 | 0.86 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL19435658 | 0.86 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL22903053 | 0.83 | NPY4R (0.48) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL4086556 | 0.82 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL1521191 | 0.82 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL1521188 | 0.82 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL2183420 | 0.82 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101693736-B | Novel peptides | 寒川贤治 | 2020-09-11 | — | — | CN | disclosed |
| US-9938332-B2 | Modified ghrelin peptides | Kanagawa, Kenji (JP) | 2018-04-10 | — | — | US | disclosed |
| US-9573986-B2 | Modified ghrelin peptides | KENJI KANGAWA (JP) | 2017-02-21 | — | — | US | disclosed |
| US-8524871-B2 | Modified gherlin peptides | Kangawa, Kenji (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20130172251-A1 | MODIFIED GHRELIN PEPTIDES | KANGAWA KENJI (JP) | 2013-07-04 | — | — | US | disclosed |
| US-8227570-B2 | Modified gherlin peptides | Kanagawa, Kenji (JP) | 2012-07-24 | — | — | US | disclosed |
| US-20110184153-A1 | MODIFIED GHERLIN PEPTIDES | KANGAWA KENJI | 2011-07-28 | — | — | US | disclosed |
| US-20090170763-A1 | Modified gherlin peptides | KANGAWA KENJI | 2009-07-02 | — | — | US | disclosed |
| US-6022696-A | SCREENING FOR MODULATORS OF INTERACTIONS BETWEEN ANGIOTENSIN LIGANDS AND ANGIOTENSIN RECEPTORS; ADDING ANGIOTENSIN LIGAND TO SAMPLE, ADDING ANGIOTENSIN LIGAND AND MODULATOR TO SECOND SAMPLE, DETERMINING BINDING CHARACTERISTICS | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2000-02-08 | — | — | US | disclosed |
| US-5945457-A | Process for preparing biologically compatible polymers and their use in medical devices | A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS, RUSSIAN ACADEMY OF SCIENCE (RU) | 1999-08-31 | — | — | US | disclosed |
| EP-0647239-A4 | ANGIOTENSIN IV PEPTIDES AND RECEPTOR. | UNIV WASHINGTON (US) | 1997-07-02 | — | — | EP | disclosed |
| EP-0647239-A1 | ANGIOTENSIN IV PEPTIDES AND RECEPTOR | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1995-04-12 | — | — | EP | disclosed |
| WO-1994000492-A1 | ANGIOTENSIN IV PEPTIDES AND RECEPTOR | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0208785-B1 | FIBRINOPHILIC UROKINASE COMPLEX AND PROCESS FOR ITS PREPARATION | SHISEIDO COMPANY LIMITED (JP) | 1992-12-30 | — | — | EP | disclosed |
| US-5004609-A | Complex with enzyme inhibitor as plasminogen activator; anticoagulants | SHISEIDO COMPANY LTD. (JP) | 1991-04-02 | — | — | US | disclosed |
| US-4851345-A | ABSORPTION DURING FIBRIN CHROMATOGRAPHY, THEN NON-ABSORPTION IN LYSINE CHROMATOGRAPHY | TERUMO KABUSHIKI KAISHA (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0181596-B1 | PROCESS FOR PREPARING A UROKINASE COMPLEX | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1989-03-22 | — | — | EP | disclosed |
| WO-1987003878-A1 | NEW 8-SUBSTITUTED DERIVATIVES OF AN ANHYDROOCTONIC ACID, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THESE AND INTERMEDIATES | Astra Läkemedel Aktiebolag (SE) | 1987-07-02 | — | — | WO | disclosed |
| EP-0208785-A1 | FIBRINOPHILIC UROKINASE COMPLEX AND PROCESS FOR ITS PREPARATION | SHISEIDO COMPANY LIMITED (JP) | 1987-01-21 | — | — | EP | disclosed |
| EP-0181596-A2 | Process for preparing a urokinase complex | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184153-A1 | MODIFIED GHERLIN PEPTIDES | GHSR, GHRHR, GHITM | NPY4R 40/4885NPY1R 92/4885NPY2R 73/4885 |
| US-20090170763-A1 | Modified gherlin peptides | GHSR, GHRHR, GHITM | NPY4R 40/4885NPY1R 92/4885NPY2R 73/4885 |
| US-20130172251-A1 | MODIFIED GHRELIN PEPTIDES | GHSR, GIPR, GHRHR | NPY4R 20/4885NPY1R 31/4885NPY2R 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.